REGN Financial Facts

Net product sales: 857.47M
Cost of goods sold: 29.9M
See Full Income Statement

Total current liabilities: 961.19M
Common Stock: 107K
See Full Balance Sheet

Regeneron Pharmaceuticals, Inc. (REGN) Earnings

  |   Expand Research on REGN
Next EPS Date 8/5/21 *Est. EPS Growth Rate +49.8% *Last Qtr.
Average EPS % Beat Rate +15.0% Revenue Growth Rate +38.3% *Last Qtr.
Average % Move 1-Wk after EPS -2.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/6/21 Q121 $9.89$9.00 +$0.89$2.53B$2.55B N/A Details
2/5/21 Q420 $9.53$8.43 +$1.10$2.42B$2.42B N/A Details
11/5/20 Q320 $8.36$7.13 +$1.23$2.29B$2.09B N/A Details
8/5/20 Q220 $7.16$5.98 +$1.18$1.95B$1.74B N/A Details
5/5/20 Q120 $6.60$6.13 +$0.47$1.83B$1.76B N/A Details
2/6/20 Q419 $7.50$6.92 +$0.58$2.17B$2.11B N/A Details
11/5/19 Q319 $6.67$6.36 +$0.31$2.05B$1.99B N/A Details
8/6/19 Q219 $6.02$5.41 +$0.61$1.93B$1.8B N/A Details